Panama - enska - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

laboratorio sanderson s.a. - amikacina (sulfato) - amikacina (sulfato)....500 mg*

Panama - enska - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

vitalis de panamÁ s.a. - amikacina (sulfato) - amikacina (sulfato)....500.00 mg

Malta - enska - Medicines Authority

norma hellas s.a. 54 menandrou str. gr-104 31 athens, greece - amikacin - solution for injection - amikacin 500 mg/2ml - antibacterials for systemic use

Malta - enska - Medicines Authority

sopharma ad 16 iliensko shosse street, 1220 sofia, bulgaria - amikacin - solution for injection - amikacin 250 milligram(s)/millilitre - antibacterials for systemic use

Malta - enska - Medicines Authority

rafarm s.a. 12, korinthou str., 15451 neo psihiko, athens, greece - amikacin - solution for injection - amikacin 250 mg/ml - antibacterials for systemic use

Bandaríkin - enska - NLM (National Library of Medicine)

insmed incorporated - amikacin (unii: 84319sgc3c) (amikacin - unii:84319sgc3c) - limited population: arikayce® is indicated in adults, who have limited or no alternative treatment options, for the treatment of mycobacterium avium complex (mac) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. as only limited clinical safety and effectiveness data for arikayce are currently available, reserve arikayce for use in adults who have limited or no alternative treatment options. this drug is indicated for use in a limited and specific population of patients. this indication is approved under accelerated approval based on achieving sputum culture conversion (defined as 3 consecutive negative monthly sputum cultures) by month 6. clinical benefit has not yet been established [see clinical studies (14)] . continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. limitati

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - amikacin sulfate, quantity: 333.65 mg/ml - injection, solution - excipient ingredients: sodium citrate dihydrate; sodium metabisulfite - short term treatment of serious infections caused by susceptible strains of gram-negative bacteria, including pseudomonas species.

Malta - enska - Medicines Authority

medicus s.a. 10 valaoritou street, 14452 metamorphosis, attika, athens, greece - amikacin sulfate - solution for injection - amikacin sulfate 250 mg/ml - antibacterials for systemic use

Bandaríkin - enska - NLM (National Library of Medicine)

general injectables & vaccines, inc - gentamicin sulfate (unii: 8x7386qrlv) (gentamicin - unii:t6z9v48ikg) - gentamicin 40 mg in 1 ml - to reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. gentamicin sulfate injection, usp is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: pseudomonas aeruginosa, proteus species (indole-positive and indole-negative), escherichia coli, klebsiella-enterobacter-serratia species, citrobacter species, and staphylococcus species (coagulase-positive and coagulase-negative). clinical studies have shown gentamicin sulfate injection, usp to be effective in bacterial neonatal sepsis; bacter

Bandaríkin - enska - NLM (National Library of Medicine)

hospira, inc. - gentamicin sulfate (unii: 8x7386qrlv) (gentamicin - unii:t6z9v48ikg) - gentamicin 40 mg in 1 ml - to reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. gentamicin sulfate injection, usp is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: pseudomonas aeruginosa , proteus species (indole-positive and indole-negative), escherichia coli , klebsiella-enterobacter-serratia species, citrobacter species, and staphylococcus species (coagulase-positive and coagulase-negative). clinical studies have shown gentamicin sulfate injection, usp to be effective in bacterial neonatal seps